Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .

Trial Details

NCT ID
NCT06471738
Phase
PHASE2
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Follicular Lymphoma Lymphoma
Interventions
  • Zanubrutinib
  • Rituximab
  • Venetoclax
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated.
  • Stage II, III, or IV disease.
  • Able and willing to provide written informed consent and to comply with the study protocol.
  • at least one measurable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Follicular Lymphoma Lymphoma Trials on Trialify →